Peritoneal surface malignancy (PSM) is a clinical entity with an unfavourable prognosis that characterises the evolution of neoplastic diseases from the abdominal and/or pelvic organs, and could also be the terminal stage of extra-abdominal tumours. [1] [2] [3] Examples of diseases that can spread mainly within the peritoneal cavity include appendiceal tumours, ovarian cancer, colorectal cancer, abdominal sarcomatosis, gastric cancer and peritoneal mesothelioma.
The Rationale for Hyperthermic

Intraperitoneal Chemotherapy
The drug concentration attainable through an IPEC instillation approach allows the intrinsic or acquired drug resistance to be overcome, simultaneously minimising the systemic toxicity. Loco-regional drug delivery under hyperthermia offers several advantages over the same procedure performed at normal temperature. At 40-42ºC, neoplastic cells become more chemosensitive due to an increase in the intracellular concentration of drugs and in their activation process -especially for alkylating agents -as well as to alterations in the DNA repair process. 5, 6 Formation of platinum DNA adducts after cisplatin exposure is enhanced and/or adduct removal is increased in heated cells, resulting in relatively higher DNA damage. 7 Table 1 summarises the most common drug association used in HIPEC.
Cytoreductive Surgery
Each procedure that composes the peritonectomy technique to achieve radical re-section of the tumour (see Figure 1 ) through CRS has a clearly defined orderly sequence of surgical manoeuvres. One or more of the following steps can be performed depending on the extension of primary surgical staging or disease extension at the time of laparotomy in order to achieve optimal residual status:
• greater omentectomy, right parietal peritonectomy and right colon re-section;
• left upper quadrant peritonectomy, splenectomy and left parietal peritonectomy;
• right upper quadrant peritonectomy and Glissonian's capsule re-section;
• lesser omentectomy, cholecystectomy, stripping of omental bursa and antrectomy;
• pelvic peritonectomy with sigmoid colon re-section with or without hysterectomy and bilateral salpingo-oophorectomy;
• other intestinal re-section and/or abdominal mass re-section; and
• bowel anastomoses.
Hyperthermic Intraperitoneal Chemotherapy
After CRS, four Tenckhoff catheters are placed in the abdominal cavity.
Two inflow catheters are placed in the right subphrenic cavity and at deep pelvic level, respectively, and two further catheters are placed in the left subphrenic cavity and in the superficial pelvic site. These catheters are connected to a device.
The Device
HIPEC requires the employment of lung-heart machine, which comprises a roller pump, a thermostat, a heat exchanger and an extra-corporeal 
The Perfusate
The perfusate, which is the liquid filling the circuit, could be of various types: peritoneal dialysis solution; 8 physiological solution; 9 or a composition of Normosol solution R pH 7.4 associated with Haemagel (in the proportion 2:1). 10 The recommended type of perfusate is isotonic salt solutions and dextrose solutions. 11
Modalities of Execution
The available modalities of execution are open, closed abdominal or semiclosed techniques. [12] [13] [14] [15] In the closed technique, the skin of the abdominal wall is temporarily closed with a running suture and the Tenckhoff catheters are connected to the circuit in order to initiate the HIPEC. 16 In the open modality, also known as the Coliseum technique, 17 the abdomen is covered with a plastic sheet and drug vapour is evacuated to protect the operating room personnel. The catheters are connected to the extra-corporeal circuit and the pre-heated polysaline perfusate containing the drug combination is instilled in the peritoneal cavity using the heart-lung pump at a mean flow of 600-800ml/min for 60-90 minutes in order to achieve an intra-abdominal temperature of 42.5ºC. 
State of the Art -Indications and Results of the Treatment
Ovarian Cancer
Ovarian cancer -with an incidence of 44,000 cases a year in Europe in 2004 -remains the most lethal of all gynaecological malignancies, being responsible for about 50% of all deaths from female genital tract cancer. 21 A recent systematic review of 14 studies published in the English literature evaluating the effects of CRS+HIPEC in patients with ovarian cancer has been carried out. 22 Seven studies showed that patients with complete cytoreduction had the greatest benefit. Median overall survival for primary and recurrent disease ranged from 22 to 54 months, and median disease-free survival from 10 to 26 months. The rates of significant morbidity associated with this combined treatment were low, ranging from 5 to 36%. The median mortality was 3% (range 0-10%).
Cytoreductive surgery combined with heated IPEC is a treatment option for patients with ovarian cancer that is worthy of further investigation.
The Italian Society of Integrated Loco-regional Therapy (SITILO) is conducting a prospective multicentre randomised study to test the effectiveness of secondary CRS associated with HIPEC in patients with epithelial ovarian cancer as second-line therapy.
Appendiceal Mucinous Tumours and Pseudomyxoma Peritonei
A recent published systematic review reported on five observational studies with relatively large series (n≥100) in patients affected by pseudomyxoma peritonei (PMP). The median survival after the treatment CRS+HIPEC ranged from 51 to 156 months. One-, two-, three-and fiveyear survival rates varied from 80 to 100%, 76 to 96%, 59 to 96% and 52 to 96%, respectively. Overall morbidity rate varied from 33 to 56%, and overall mortality rates ranged from 0 to 18%. In summary, some promising long-term results were observed compared with historical controls. Due to the rarity of this disease, a well designed, prospective, multi-institutional study would be meaningful. 23 
Peritoneal Mesothelioma
According to an epidemiological study conducted in six western European countries, projections for the period 1995-2029 suggest that the number of men dying from mesothelioma each year will almost Resectable PC from ovarian cancer after first-line chemotherapy* Peritoneal mesothelioma 30, 31 Resectable PC from colorectal cancer [32] [33] [34] [35] [36] Mucinous tumour from the appendix with Pseudomyxoma peritonei 37, 38 Carcinoma of the appendix with resectable PC A recent systematic review evaluated the current evidence for CRS and peri-operative IPEC for diffuse malignant peritoneal mesothelioma (PSM). 25 Seven observational studies were available for assessment; these demonstrated an improved overall survival compared with historical controls using systemic chemotherapy and palliative surgery. The median survival ranged from 34 to 92 months. One-, three-and five-year survival varied from 60 to 88%, 43% to 65% and 29% to 59%, respectively.
Peri-operative morbidity varied from 25 to 40% and mortality ranged from 0 to 8%.
Conclusion
Loco-regional treatment for PSM is attracting increasing interest from the scientific community. The procedure is time-and labour-consuming: the mean duration of the procedure, according to the National Cancer 
